MRNA: Bullish Setup Ahead of Earnings & FOMCMRNA: Bullish Setup Ahead of Earnings & FOMC
Moderna (MRNA) appears to have found a bottom near $23.50, based on recent price behavior. Following that level, the stock began accumulating, suggesting renewed buying interest. This was confirmed when MRNA decisively broke above $28.50, signaling a sh
Key facts today
Moderna's EP'949 patent was upheld by the U.K. Court of Appeal, confirming Pfizer and BioNTech's COVID-19 vaccine infringement, entitling Moderna to damages for sales post-March 2022.
Moderna is working on a COVID-flu combo vaccine to boost falling COVID vaccine sales and is engaging with regulators to clarify data needed for resubmitting its approval application.
Moderna has cut its 2025 sales forecast to $1.5 billion to $2.2 billion, lowering the upper limit by $300 million due to delayed UK revenue deliveries now expected in early 2026.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−8.060 EUR
−3.44 B EUR
3.13 B EUR
342.49 M
About Moderna, Inc.
Sector
Industry
CEO
Stéphane Bancel
Website
Headquarters
Cambridge
Founded
2010
FIGI
BBG011RJBSB9
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Related stocks
MRNA Approaching Trend Shift After Multi-Month DeclinePotential trend flip on the Moderna Chart for the first time since May 2024. I use a default doubled cloud on the daily timeframe 18/52/104/26. I find this to be superior to the default cloud on both backtesting and forward testing over the past decade on any chart.
Ideal bullish entry conditions
Bullish Analysis for Moderna (MRNA)Recent Price Action Shows Strength MRNA has shown significant bullish momentum since mid-May 2025, rising from around $24 to current levels above $34, representing a 40%+ gain. The stock has formed a series of higher lows and higher highs, establishing a clear uptrend.
Key Bullish Factors:
Positiv
MRNA looking strong at cmpModerna remains in a precarious transition phase—from COVID-revenue dependency toward a diversified vaccine portfolio. Technically, momentum favors upside in the short-term, but fundamentals and macro-regulatory factors suggest caution. If its RSV and flu/COVID combo rollouts succeed and regulatory
MRNA: The Wager No One Wants to Talk AboutModerna (MRNA) has become a pariah in many portfolios. Between reputational overhangs, political weaponization of its COVID success, and fresh regulatory pressures like the labeling requirement just triggered by Florida, the company has seemingly absorbed wave after wave of bad press.
But that’s th
$MRNA – Long-Term Setup Brewing | Major Move Incoming?Moderna ( NASDAQ:MRNA ) may be gearing up for a multi-month reversal after a prolonged downtrend. Price action is compressing in a tight base, suggesting a potential 6+ month breakout could be in the cards.
📊 Key Technical Notes:
Trading near long-term support with signs of accumulation
Bullish d
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where MRNA is featured.
Frequently Asked Questions
The current price of MRNA is 23.545 EUR — it has decreased by −5.93% in the past 24 hours. Watch MODERNA INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on VIE exchange MODERNA INC stocks are traded under the ticker MRNA.
MRNA stock has fallen by −9.97% compared to the previous week, the month change is a 14.11% rise, over the last year MODERNA INC has showed a −78.68% decrease.
We've gathered analysts' opinions on MODERNA INC future price: according to them, MRNA price has a max estimate of 168.66 EUR and a min estimate of 17.04 EUR. Watch MRNA chart and read a more detailed MODERNA INC stock forecast: see what analysts think of MODERNA INC and suggest that you do with its stocks.
MRNA reached its all-time high on Aug 10, 2021 with the price of 423.850 EUR, and its all-time low was 20.805 EUR and was reached on Apr 7, 2025. View more price dynamics on MRNA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
MRNA stock is 13.55% volatile and has beta coefficient of 1.08. Track MODERNA INC stock price on the chart and check out the list of the most volatile stocks — is MODERNA INC there?
Today MODERNA INC has the market capitalization of 10.01 B, it has decreased by −5.93% over the last week.
Yes, you can track MODERNA INC financials in yearly and quarterly reports right on TradingView.
MODERNA INC is going to release the next earnings report on Oct 30, 2025. Keep track of upcoming events with our Earnings Calendar.
MRNA earnings for the last quarter are −1.81 EUR per share, whereas the estimation was −2.54 EUR resulting in a 28.75% surprise. The estimated earnings for the next quarter are −1.63 EUR per share. See more details about MODERNA INC earnings.
MODERNA INC revenue for the last quarter amounts to 120.54 M EUR, despite the estimated figure of 94.06 M EUR. In the next quarter, revenue is expected to reach 994.63 M EUR.
MRNA net income for the last quarter is −897.54 M EUR, while the quarter before that showed −1.08 B EUR of net income which accounts for 17.04% change. Track more MODERNA INC financial stats to get the full picture.
No, MRNA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Aug 1, 2025, the company has 5.8 K employees. See our rating of the largest employees — is MODERNA INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MODERNA INC EBITDA is −3.27 B EUR, and current EBITDA margin is −116.07%. See more stats in MODERNA INC financial statements.
Like other stocks, MRNA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MODERNA INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MODERNA INC technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MODERNA INC stock shows the sell signal. See more of MODERNA INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.